- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05823636
The Clinical Course and Factors for the Progression of Uninvestigated Dyspepsia to Functional Dyspepsia
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Yanglin Pan, MD
- Phone Number: 13991811225
- Email: yanglinpan@hotmail.com
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710032
- Recruiting
- Air Force Military Medical University, China
-
Contact:
- Yanglin Pan, MD
- Phone Number: 13991811225
- Email: yanglinpan@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients aged ≥ 18 years old who had first-onset dyspepsia with one or more symptoms of epigastric pain, epigastric burning, postprandial fullness, early satiation and that has lasted for more than 1 month to 3 months.
Exclusion Criteria:
Patients with local or systemic diseases which may cause dyspeptic symptoms:
Known active peptic ulcer, cholecystitis, gallstone, gastrointestinal obstruction, gastroparesis, and etc.
- Known acute or chronic injury of liver or kidney
- Obvious hematological abnormality, or endocrine and metabolic diseases
- Known malignancy; Obvious cardiovascular or cerebrovascular diseases (such as coronary heart disease, arrhythmia, cerebral infarction and etc.
- Other conditions which may be associated with dyspeptic symptoms (such as NSAIDs associated dyspepsia)
- organ failure defined by Marshall standard or severe psychiatric illnesses
- pregnancy or lactation
- unable to provide consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
uninvestigated dyspepsia
Patients aged ≥ 18 years old who had first-onset dyspepsia with one or more symptoms of epigastric pain, epigastric burning, postprandial fullness, early satiation and that has lasted for more than 1 month to 3 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional dyspepsia defined by ROME IV criteria
Time Frame: 6 months
|
Met the following criteria: by one or more of the following symptoms: postprandial fullness, early satiation, epigastric pain, and epigastric burning that are unexplained after a routine clinical evaluation, Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Global Overall Symptom score (GOSS)
Time Frame: 1month, 3 months, 6 months
|
The GOSS consists of 10 cardinal items (epigastric pain, epigastric discomfort, Heartburn, acid regurgitation, upper abdominal bloating, belching, nausea, early satiety, postprandial fullness, other epigastric symptoms(eg.
epigastric burning).
Each item can be scored from 1 (no) to 7 (worst).
|
1month, 3 months, 6 months
|
|
Short Form of Nepean Dyspepsia Index (SF-NDI)
Time Frame: 1month, 3 months, 6 months
|
The SF-NDI consists of 10 questions regarding the effects of dyspepsia symptoms ("stomach problems") on different aspects of life (tension, interference with daily activities, eating/drinking, knowledge/control, and work/study).
Each response can be from 1 (not at all affected) to 5 (extremely affected), or 0 (N/A), for a total summed score out of 50.
|
1month, 3 months, 6 months
|
|
Hospital anxiety and depression scale
Time Frame: 1month, 3 months, 6 months
|
Anxiety and depression of patients are assessed by using Hospital Anxiety and Depression Scale.It contains 14 items (7 anxiety and 7 depression), which assess symptoms experienced during the past week on a 0-3 scale.
A subscore of > 8 for depression or anxiety would indicate a clinical case.
|
1month, 3 months, 6 months
|
|
Functional dyspepsia defined by Asia criteria:
Time Frame: 3 month
|
Met the following criteria: by one or more of the following symptoms: postprandial fullness, early satiation, epigastric pain, and epigastric burning that are unexplained after a routine clinical evaluation, the symptoms duration≧3 months.
|
3 month
|
|
Number of participants subclassified into different subtypes of functional dyspepsia defined by ROME IV criteria
Time Frame: 6 months
|
Functional dyspepsia was classified into three subgroups:(1) Postprandial Distress Syndrome, defined as Bothersome postprandial fullness or/and Bothersome early satiation.
(2) Bothersome epigastric pain AND/OR Bothersome epigastric burning.
(3) mixed syndrome, defined when postprandial distress syndrome and epigastric pain syndrome presented simultaneously.
|
6 months
|
|
Quality of Life scores
Time Frame: 1month, 3 months, 6 months
|
Quality of Life scores assessed by Patient-reported outcomes measurement information system (PROMIS) Global-10 questionnaire. PROMIS Global-10 is a newly validated 10-question survey used to assess health care-related quality of life measures for the general population. It's a 10-item patient-reported questionnaire in which the response options are presented as 5-point (as well as a single 11-point) rating scales. These scores are then standardized to the general population, using the "T-Score". The average "T-Score" for the United States population is 50 points, with a standard deviation of 10 points. Higher scores indicate a healthier patient and a better quality of life. |
1month, 3 months, 6 months
|
|
Self-reported severity of symptoms by patients
Time Frame: 1 day
|
Patients rated the severity of dyspepsia as mild, moderate, and severe by themselves
|
1 day
|
|
Number of participants with other functional gastrointestinal diseases defined by ROME IV criteria
Time Frame: 1 day
|
Recurrent functional dysphagia, reflux hypersensitivity, irritable bowel syndrome, etc.
|
1 day
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KY20222180-F-5
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.